Clinical comprehensive evaluation of drugs for acute ischemic stroke
WANG Yu-fei
JI Xin-yue
TIAN Lei
Abstract：Objective:To conduct a comprehensive clinical evaluation of drugs for acute ischemic stroke(AIS)such as butylphthalide,edaravone,uricilin,and edaravone borneol to clarify their clinical application values.Methods:This study evaluated the aforementioned drugs from five dimensions:efficacy,safety,cost-effectiveness,accessibility,and appropriateness,based on literature and publicly available data.Results:There were no significant differences in efficacy and safety among the evaluated drugs.However,butylphthalide showed a relatively higher probability of superiority in the surface under the cumulative ranking curve(SUCRA)ranking.Additionally,it performed better in terms of use convenience,medical insurance coverage,and patient cost burden,resulting in good comprehensive suitability.Clinicians can make selections based on patients'specific needs.Conclusion:Butylphthalide has better comprehensive clinical value in the treatment of acute ischemic stroke,especially in terms of cost-effectiveness and appropriateness.This study can provide a reference for the formulation of relevant drug policies and clinical medication decisions.
Keywords：acute ischemic strokebutylphthalideedaravoneuricilinedaravone borneolclinical comprehensive evaluation
Publication Date：2026-01-30
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：7( 213-219 )